CNTX Valuation

Context Therapeutics Inc

Add to Watchlist

Advanced Chart

0.841

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

CNTX Relative Valuation

CNTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CNTX is overvalued; if below, it's undervalued.

Historical Valuation

Context Therapeutics Inc (CNTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.80. The fair price of Context Therapeutics Inc (CNTX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.84

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.83

P/B

Median3y

1.09

Median5y

0.97

-20.50

FCF Yield

Median3y

-67.72

Median5y

-59.20

Competitors Valuation Multiple

The average P/S ratio for CNTX's competitors is 2.96, providing a benchmark for relative valuation. Context Therapeutics Inc Corp (CNTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CNTX.O

Context Therapeutics Inc

Loss

Average P/S: 2.96

75.44M